
    
      The duration per patient is up to 85 weeks, including a Screening Period consisting of a
      Screening phase of up to 2 weeks and a 2-week single-blind Run-in phase, a 26-week double
      blind Core Treatment Period, a 53 week double blind Extension, and a 2-week post treatment
      Follow-up period to collect safety information.
    
  